A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

NCT06744205 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

1162

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Healthy Volunteers

Interventions

BIOLOGICAL: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
BIOLOGICAL: TIV mRNA-neuraminidase (NA)
BIOLOGICAL: TIV mRNA-HA Vaccine 2
BIOLOGICAL: Quadrivalent Influenza Standard Dose Vaccine
BIOLOGICAL: Quadrivalent Influenza Vaccine High Dose

Sponsor

Sanofi Pasteur, a Sanofi Company